Loading organizations...
§ Corporate Venture Capital · USA
Corporate VC investing in early-stage biotech, focusing on oncology, regenerative medicine, and auto-immunity.
Established in 2010, the Boehringer Ingelheim Venture Fund is a corporate venture capital arm based in Ingelheim am Rhein, Germany, that invests in early stage biotechnology companies and preclinical therapeutic assets. The evergreen fund primarily targets Seed and Series A rounds, focusing on groundbreaking innovations in oncology, regenerative medicine, autoimmunity, infectious diseases, and digital health solutions. Operating with a €350 million capital pool, the firm takes minority equity stakes and secures board seats to provide strategic support and scientific expertise to its partners. The organization manages a portfolio of over 40 direct investments and has facilitated at least six exits directly to its parent company, Boehringer Ingelheim. Key leadership includes Global Head of Investment Frank Kalkbrenner, Managing Director Fei Shen, and Investment Director Hu Sheng Qian, who oversee the corporate fund and its strategic direction.
Key people at Boehringer Ingelheim Venture Fund.
Key people at Boehringer Ingelheim Venture Fund.
Boehringer Ingelheim Venture Fund (BIVF) is a corporate venture capital fund focused on investing in pioneering biotechnology and health tech startups that develop first-in-class, disease-modifying therapeutics. Its mission is to advance groundbreaking science that can redefine the standard of care and significantly improve patient outcomes, particularly in areas of high medical need such as immuno-oncology, regenerative medicine, infectious diseases, and digital health. BIVF seeks to build long-term partnerships with scientists and entrepreneurs to translate innovative biomedical research into clinical applications, targeting novel platform technologies, new generation vaccines, and biological entities like oncolytic virotherapy[1][2][4].
Founded in 2010 as part of the global pharmaceutical company Boehringer Ingelheim, the fund leverages the parent company's deep expertise and global network to support early to growth-stage ventures primarily in North America and Europe. Key leadership includes Dr. Detlev Mennerich, the Global Head of BIVF. Over time, the fund has evolved to emphasize an operator-first investment approach, engaging actively with portfolio companies to accelerate value creation. It also collaborates with other innovation ecosystem players such as High-Tech Gründerfonds to foster entrepreneurship in life sciences[3][4][5].
BIVF rides the wave of increasing demand for innovative therapies addressing unmet medical needs, especially in immuno-oncology and regenerative medicine. The timing is critical as advances in biotechnology, digital health, and AI-driven drug discovery converge, enabling new therapeutic modalities. By investing in novel platforms and biological entities, BIVF influences the ecosystem by accelerating the translation of cutting-edge science into viable treatments, thus shaping future healthcare paradigms[1][2][4].
Looking ahead, BIVF is poised to deepen its impact by continuing to back transformative science that challenges existing treatment standards. Trends such as personalized medicine, AI integration in drug development, and antimicrobial resistance solutions will likely shape its investment focus. As the biotech innovation landscape grows more complex and competitive, BIVF’s strategic alignment with Boehringer Ingelheim’s R&D capabilities positions it to remain a key player in fostering breakthrough therapies that improve patient care globally[6][7].
In summary, Boehringer Ingelheim Venture Fund stands out as a mission-driven investor dedicated to pioneering biomedical innovation, leveraging its pharmaceutical heritage and network to catalyze the next generation of life-saving medicines.
Boehringer Ingelheim Venture Fund has more than 26 tracked investments across 23 companies. The latest tracked deal is $8.0M Seed in STRM in January 2026.
